Last reviewed · How we verify
ALTROPANE
ALTROPANE is a altropane drug. It is currently in Phase 3 development.
ALTROPANE works by binding to and inhibiting a specific target, although the exact target is unknown.
ALTROPANE is a small molecule drug in the altropane class, developed by an unknown original developer and currently owned by an unknown entity. Its target and exact mechanism of action are not specified. ALTROPANE is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are unknown. Key safety considerations are not available due to the lack of FDA approval. Further research is needed to understand the pharmacology and clinical utility of ALTROPANE.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALTROPANE |
|---|---|
| Drug class | altropane |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Think of ALTROPANE like a key that fits into a lock. The lock is a specific protein in the body, and when the key (ALTROPANE) binds to it, it can either turn off or turn on a particular process. This process is what we're trying to understand and control with ALTROPANE.
Approved indications
Common side effects
Key clinical trials
- Altropane Dose for Imaging Patients With Suspected Parkinson's Disease (PHASE2)
- Depression and Dopamine Transporter Function Study Using C-11 Altropane
- ALTROPANE® SPECT Imaging in Patients With Parkinson Disease (PHASE2)
- Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate (PHASE1,PHASE2)
- An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects (PHASE4)
- An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD
- Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor (PHASE3)
- 123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALTROPANE CI brief — competitive landscape report
- ALTROPANE updates RSS · CI watch RSS
Frequently asked questions about ALTROPANE
What is ALTROPANE?
How does ALTROPANE work?
What drug class is ALTROPANE in?
What development phase is ALTROPANE in?
Related
- Drug class: All altropane drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing